The use of an anti-PSMA x anti-CD3 bispecific diabody to selectively activate PSMA-specific CD8+ and CD4+ T cells and to recruit them to the tumor site revealed efficient inhibition of tumor growth in a xenograft model [62,63]. This evidence concerns the gene FOLH1 and neoplasm.